PRF Technologies Ltd. (PRFX)
NASDAQ: PRFX · Real-Time Price · USD
2.080
-0.280 (-11.86%)
At close: Mar 27, 2026, 4:00 PM EDT
2.130
+0.050 (2.40%)
After-hours: Mar 27, 2026, 6:33 PM EDT
PRF Technologies Employees
As of December 31, 2024, PRF Technologies had 6 total employees, including 2 full-time and 4 part-time employees. The number of employees decreased by 1 or -14.29% compared to the previous year.
Employees
6
Change (1Y)
-1
Growth (1Y)
-14.29%
Revenue / Employee
$2,833
Profits / Employee
-$806,333
Market Cap
1.63M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 6 | -1 | -14.29% | 2 | 4 |
| Dec 31, 2023 | 7 | 1 | 16.67% | 7 | 0 |
| Dec 31, 2022 | 6 | 2 | 50.00% | 6 | 0 |
| Dec 31, 2021 | 4 | 2 | 100.00% | 4 | 0 |
| Dec 31, 2020 | 2 | - | - | 1 | 1 |
Related Stocks
Employee RankingsPRFX News
- 1 day ago - PRF Technologies Provides Year-End 2025 Business Update Highlighting Strategic Progress Across Healthcare and AI-Driven Solar Platforms - GlobeNewsWire
- 11 days ago - PRF Technologies Ltd. Announces Commercial Collaboration Agreement with Blade Ranger to Accelerate Large-Scale DeepSolar Commercial Engagements - GlobeNewsWire
- 5 weeks ago - PRF Technologies' DeepSolar Announces its First Commercial Due Diligence Engagement with EDF Power Solutions Israel, a Global Leader in Renewable Energy - GlobeNewsWire
- 6 weeks ago - PRF Technologies Wins Another European Utility-Scale Solar Deployment, Expanding DeepSolar's Installed Commercial Base - GlobeNewsWire
- 2 months ago - PRF Technologies Files Its First Patent Application for Solar Plant Micro-Climate Forecast Modeling Designed to Improve Energy Production Forecast Accuracy - GlobeNewsWire
- 2 months ago - PainReform Stock Spikes As It Rebrands, Expands Beyond Pharma With AI, Clean Energy Push - Benzinga
- 2 months ago - PainReform Ltd. Changes Name to PRF Technologies Ltd. - GlobeNewsWire
- 2 months ago - PainReform's LayerBio's Drop-Less OcuRing™-K Delivery Platform Demonstrates Favorable Safety Profile in Preclinical and Phase I Clinical Studies - GlobeNewsWire